Ad-hoc | 26 April 2017 17:42

Biotest AG: Biotest recalls human albumin and reduces forecast

Biotest AG / Key word(s): Profit Warning

26-Apr-2017 / 17:42 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

/
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)

Biotest recalls human albumin and reduces forecast

Dreieich, 26 April 2017. In close co-operation with regulatory authorities, Biotest performed a batch recall of human albumin (Albiomin(R)) 5% und 20% Biotest injection solution. The batches in question had already been quarantined by Biotest on 13 April 2017.

Financial consequences of the one-time effect are currently being evaluated. As a precautionary measure, Biotest reduces its sales guidance from single-digit growth rate to the level of the previous year and its EBIT guidance of EUR46 to EUR48 million by EUR25 to EUR30 million.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.de

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Contact:
Dr. Michael Ramroth
Chief Financial Officer
Biotest AG
Landsteinerstr. 3
63303 Dreieich
Tel. +40 6103 801 338
Fax: +49 6103 801 347
Michael.ramroth@biotest.com

26-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Biotest AG
	Landsteinerstraße 5
	63303 Dreieich
	Germany
Phone:	0 61 03 – 8 01-0
Fax:	0 61 03 – 8 01-150
E-mail:	investor_relations@biotest.de
Internet:	http://www.biotest.de
ISIN:	DE0005227235, DE0005227201
WKN:	522723, 522720
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

End of Announcement DGAP News Service